Table 1.
Demographics, cardiovascular risk factors, respiratory function, chronic lung infections, and medications of patients on the lung transplant list.
| Study Population n = 49 | |
|---|---|
| Demographics, n (%) | |
| Age, mean (SD) years | 38 (± 15) |
| Female | 30 (61) |
| Body mass index, mean (SD) | 21.8 (± 3.8) |
| Lung Allocation Score, median (IQR) | 33.777 (32.4–37.5) |
| Cystic fibrosis | 32 (65.5) |
| Idiopathic pulmonary fibrosis | 5 (10) |
| Chronic obstructive pulmonary disease | 3 (6) |
| Nonspecific interstitial pneumonia | 2 (4) |
| Systemic scleroderma | 2 (4) |
| Other indications for lung transplant | 5 (10) |
| Cardiovascular risk factors, n (%) | |
| Hypertension | 6 (12) |
| Diabetes | 20 (41) |
| Pulmonary hypertension | 12 (24.5) |
| mPAP, mean (SD) mmHg | 22 (± 5) |
| Respiratory function, median (IQR) | |
| Exacerbations, n (%) | 32 (65.5) |
| P/F, mean (SD) | 305 (± 61) |
| pCO2, mmHg | 42 (38–48) |
| FEV1 % of predicted | 31 (24–49) |
| FVC % of predicted, mean (SD) | 54 (± 16) |
| FEV1/FVC ratio, mean (SD) | 60 (± 21) |
| DLCO, mean (SD) % | 45 (± 22) |
| 6MWT, mean (SD) m | 406 (± 169) |
| Chronic lung infections, n (%) | |
| Burkholderia cepacia | 1 (2) |
| Pseudomonas aeruginosa | 27 (55) |
| MRSA | 9 (18.5) |
| Aspergillus | 8 (16.5) |
| Candida albicans | 3 (6) |
| NTM | 3 (6) |
| Medications, n (%) | |
| Beta-blockers | 7 (14.5) |
| Beta-agonists | 37 (75.5) |
| Anticholinergics | 12 (24.5) |
| Endothelin Receptor Antagonists | 1 (2) |
| Prostanoids | 2 (4) |
| PDE5 inhibitors | 1 (2) |
| Steroids | 40 (81.5) |
| Oxygen | 37 (75.5) |
n, number; SD, standard deviation; IQR 25–75, interquartile range; mPAP, mean pulmonary arterial pressure; mmHg, millimeter of mercury; P/F: ratio of arterial oxygen partial pressure to fractional inspired oxygen; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; DLCO, diffusing capacity of the lung for carbon monoxide; 6MWT, 6 min walking test; MRSA, methicillin-resistant Staphylococcus aureus; NTM, non-tuberculous Mycobacteria; PDE-5, phosphodiesterase type 5.